retatrutide ema approval (LY3437943) | GCGR/GLP-1R Inhibitor retatrutide ema approval RETATRUTIDE
Description
The GRADE framework assesses the quality of evidence across five domains: risk of bias, directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias
Published 2025 Feb 5
Once weekly
Dose escalation GRAPHICAL ABSTRACT INTRODUCTION Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes mellitus (T2DM) due to their dual effects on glycemic control and body weight
When a person stops taking the medication, its effects halt, too, and a person may return to their previous calorie consumption
